A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome
2006

Economic Modeling of Neuromuscular Blockade in ARDS Patients

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): Macario Alex, Chow John L, Dexter Franklin

Primary Institution: Stanford University School of Medicine

Hypothesis

Would a reduction in intubation time of 6 hours and/or a reduction in the incidence of AQMS from 25% to 21% provide enough benefit to justify an additional expenditure of $267?

Conclusion

ARDS patients receiving a neuromuscular blocker have a high mortality and unpredictable outcomes, leading to large variability in costs per case.

Supporting Evidence

  • The mean cost for ARDS patients receiving standard care for 6 months was predicted to be $62,238.
  • 39% of hypothetical patients with ARDS would be expected to be dead after 6 months.
  • The net monetary benefit of reducing both AQMS and ventilation time would be positive for only 51% of patients.

Takeaway

This study used a computer model to see if using a certain drug for ARDS patients is worth the extra money, but found that it might not help much.

Methodology

A Markov model was designed with hypothetical patients in 1 of 6 mutually exclusive health states over a period of 6 months.

Limitations

A prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU is impractical due to the highly variable clinical course of patients with ARDS.

Participant Demographics

Base case was a 55 year-old man in the ICU with ARDS.

Statistical Information

Confidence Interval

$42,259 – $83,766

Digital Object Identifier (DOI)

10.1186/1472-6947-6-15

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication